Nuvectis Pharma annual ebitda
2022
2023
2024
2025
Nuvectis Pharma EBITDA Growth & History (NVCT)
Nuvectis Pharma's calculated EBITDA was −$27.6M for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$27.6M | −$7.7M | — |
| 2024 | 2024-12-31 | −$19.8M | $3.0M | — |
| 2023 | 2023-12-31 | −$22.9M | −$3.7M | — |
| 2022 | 2022-12-31 | −$19.2M | — | — |
Nuvectis Pharma quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.2M | −$602,000 | — |
| Q1 2026 | 2026-03-31 | −$6.3M | — | — |
| Q4 2025 | 2025-12-31 | −$7.6M | — | — |
| Q3 2025 | 2025-09-30 | −$7.8M | — | — |
| Q2 2025 | 2025-06-30 | −$6.6M | — | — |
Nuvectis Pharma ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Nuvectis Pharma's ebitda decreased from −$19.2M to −$27.6M, a change of −$8.3M. The latest reported quarter, Q2 2026, shows −$7.2M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗Community posts
Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease ...
